 They can be identified by the presence of estrogen receptors (ER+) and progesterone receptors (PR+) on their surface (sometimes referred to together as hormone receptors).These ER+ cancers can be treated with drugs that either block the receptors, e.g.tamoxifen, or alternatively block the production of estrogen with an aromatase inhibitor, e.g.